MRUS Merus N.V.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 14 May 2020 Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates

   – MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers –– MCLA-117 demonstrates limited clinical activity in Phase 1 trial –– Extensive

2. 11 May 2020 Merus Announces Financial Results for the First Quarter and Provides Business Update

   MCLA-128, zenocutuzumab, Phase 1/2 eNRGy trial remains on track MCLA-117 program update to be presented at upcoming medical meeting Anand Mehra, M.D. to succeed Russell Greig, Ph.D. as Chairman and Paolo Pucci

3. 06 April 2020 Merus N.V.: Throsby Mark (EVP & Chief Scientific Officer) Sells 368 @ Avg Price: $10.93 (Form4)

4. 12 March 2020 Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update

   UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific

5. 09 January 2020 ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region

   VICTORIA and UTRECHT, The Netherlands, Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery

6. 16 December 2019 Merus Announces Chief Executive Officer Transition

   — Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer —— Ton Logtenberg, Ph.D., to step down after 16 years of leadership —— Transition to occur December 31, 2019 — UTRECHT, The Netherlands and

7. 12 November 2019 Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update

   UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage company developing innovative, full-length bispecific

8. 05 November 2019 Merus Announces Pricing of Public Offering of Common Shares

   UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an

9. 04 November 2019 Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

   UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the launch of a proposed

10. 27 October 2019 Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

    Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

11. 25 October 2019 Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage bispecific antibody company developing Biclonics®, innovative